Regulatory Status: Retatrutide is an investigational compound in phase 3 clinical trials (as of June 29, 2025) and is not approved by the FDA or any other regulatory body for clinical use
Those averaging under 50 ounces accounted for three hospitalizations for dehydration and two for acute kidney issues
In controlled pre-clinical and laboratory settings, Retatrutide has been studied across a wide range of metabolic, endocrinological, and physiological research applications: Triple Incretin Receptor Research Retatrutides defining research application is the simultaneous activation of GLP-1R, GIPR, and GCGR enabling researchers to study the combined tri-agonist incretin effect, examine the distinct contribution of each receptor to overall metabolic outcomes, and explore the additive and synergistic interactions between all three receptor systems in ways no prior compound has allowed
It mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central pathways
Cold, dark, and dry conditions stretch this timeline, while heat, light, or sloppy handling shrink it
